Vericiguat is primarily used to treat symptomatic chronic heart failure, particularly in patients with reduced ejection fraction.
Vericiguat may be considered when a patient's left ventricular ejection fraction (LVEF) is below 40%.
If a patient is intolerant to or does not respond well to other heart failure medications, such as beta-blockers, ACE inhibitors/ARBs, or MRAs, vericiguat may be an option.
Vericiguat may be part of the treatment regimen during worsening heart failure symptoms or acute decompensated heart failure.
Vericiguat is typically used in combination with other heart failure medications to provide a more comprehensive treatment effect.
The use of vericiguat may be based on clinical trial results that assess its safety and efficacy in specific patient populations.
Vericiguat should be used under the evaluation and guidance of a doctor, who will consider the patient's overall health, disease severity, and other relevant factors.